Point72 Asset Management L.P. 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 7:47 pm Sale |
2024-09-30 | 13G | Celldex Therapeutics, Inc. CLDX |
Point72 Asset Management L.P. | 1,684,032 2.500% |
-1,072,090 (-38.90%) |
Filing |
| 2024-02-14 4:17 pm Sale |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Point72 Asset Management L.P. | 2,756,122 5.000% |
-866,014 (-23.91%) |
Filing |
| 2023-11-20 4:15 pm Purchase |
2023-11-10 | 13G | Celldex Therapeutics, Inc. CLDX |
Point72 Asset Management L.P. | 3,622,136 6.600% |
3,622,136 (New Position) |
Filing |